Advanced search
Publication Cover
Leukemia & Lymphoma Volume 47, 2006 - Issue 6
Submit an article Journal homepage
227
Views
43
CrossRef citations to date
0
Altmetric
Original

Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma

Dr Niklas Zojer First Department of Medicine, Center for Oncology and Hematology, WilhelminenspitalCorrespondence[email protected]
,
Klaus Kirchbacher First Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital
,
Michael Vesely Department for Pathology, Hospital Lainz
,
Wolfgang Hübl Central Laboratory, Wilhelminenspital, Vienna, Austria
&
Heinz Ludwig First Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital
Pages 1103-1109 | Received 30 Aug 2005, Accepted 28 Dec 2005, Published online: 01 Jul 2009

Citations (43)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (9)

Flora Zagouri, Evangelos Terpos, Efstathios Kastritis & Meletios A. Dimopoulos. (2016) Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs 21:2, pages 225-237.
Read now
Yulian Khagi & Tomer M Mark. (2014) Potential role of daratumumab in the treatment of multiple myeloma. OncoTargets and Therapy 7, pages 1095-1100.
Read now
Francesca Donato, Francesca Gay, Sara Bringhen, Rossella Troia & Antonio Palumbo. (2014) Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. Expert Opinion on Biological Therapy 14:8, pages 1127-1144.
Read now
Bushra Ajaz, Adnan Akhtar, Chung-Che Chang, Melhem Solh, Kay Tangonan & Yasser Khaled. (2014) Plasma cell CD20 expression: primary aberrant expression or receptor up-regulation. Leukemia & Lymphoma 55:2, pages 444-446.
Read now
Enrique M Ocio, Constantine S Mitsiades, Robert Z Orlowski & Kenneth C Anderson. (2014) Future agents and treatment directions in multiple myeloma. Expert Review of Hematology 7:1, pages 127-141.
Read now
Junya Kuroda, Hisao Nagoshi, Yuji Shimura & Masafumi Taniwaki. (2013) Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Review of Anticancer Therapy 13:9, pages 1081-1088.
Read now
Hitoshi Ohno. (2010) Long-term response to maintenance treatment with rituximab in CD20+ multiple myeloma. Leukemia & Lymphoma 51:11, pages 2144-2146.
Read now
Tomer Mark, Peter Martin, John P Leonard & Ruben Niesvizky. (2009) Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs 18:1, pages 99-104.
Read now
Rachid Baz, Suzanne Fanning, Lori Kunkel, Sameh Gaballa, Mary Ann Karam, Janice Reed, Megan Kelly & Mohamad Hussein. (2007) Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leukemia & Lymphoma 48:12, pages 2338-2344.
Read now

Articles from other publishers (34)

Neret Pujol-Navarro, Mohammed M Al Qaraghuli, Karina Kubiak-Ossowska, Manal M Alsaadi, Gillian A Horne, Richard L Soutar, Elpiniki Paspali, Valerie A Ferro, Mark TS Williams & Paul A Mulheran. (2021) Multiple myeloma: therapeutic delivery of antibodies and aptamers. Therapeutic Delivery 12:10, pages 705-722.
Crossref
James Ackley, Miguel Armenta Ochoa, Delta Ghoshal, Krishnendu Roy, Sagar Lonial & Lawrence H. Boise. (2021) Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. Cancers 13:19, pages 4787.
Crossref
A. Deyà-Martínez, A. Alonso-Saladrigues, A. P. García, A. Faura, M. Torrebadell, A. Vlagea, A. Català, A. Esteve-Solé, M. Juan, S. Rives & L. Alsina. (2020) Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. Bone Marrow Transplantation 56:2, pages 376-386.
Crossref
Amandeep Godara & Giovanni Palladini. (2020) Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis. Hematology/Oncology Clinics of North America 34:6, pages 1145-1159.
Crossref
Lei Kang, Dawei Jiang, Christopher G. England, Todd E. Barnhart, Bo Yu, Zachary T. Rosenkrans, Rongfu Wang, Jonathan W. Engle, Xiaojie Xu, Peng Huang & Weibo Cai. (2018) ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. European Journal of Nuclear Medicine and Molecular Imaging 45:8, pages 1372-1381.
Crossref
Roberto De Luca, Paul Kachel, Klara Kropivsek, Berend Snijder, Markus G Manz & Dario Neri. (2018) A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies. Protein Engineering, Design and Selection 31:5, pages 173-179.
Crossref
Shmuel Yaccoby. (2018) Two States of Myeloma Stem Cells. Clinical Lymphoma Myeloma and Leukemia 18:1, pages 38-43.
Crossref
Carolina Martínez-Cingolani & Jean Christophe Bories. (2016) Development of chimeric antigen receptors for multiple myeloma. Biochemical Society Transactions 44:2, pages 397-405.
Crossref
Susan J. Lee & Ivan Borrello. 2016. Plasma Cell Dyscrasias. Plasma Cell Dyscrasias 207 225 .
Ayed O. Ayed, Lung-Ji Chang & Jan S. Moreb. (2015) Immunotherapy for multiple myeloma: Current status and future directions. Critical Reviews in Oncology/Hematology 96:3, pages 399-412.
Crossref
Sandy W. Wong & Raymond L. Comenzo. (2015) CD38 Monoclonal Antibody Therapies for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 15:11, pages 635-645.
Crossref
K. Martin Kortuem, Kaitlyn Zidich, Steven R. Schuster, Meaghan L. Khan, Victor H. Jimenez-Zepeda, Joseph R. Mikhael, Rafael Fonseca & A. Keith Stewart. (2014) Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 14:4, pages 284-290.e5.
Crossref
Benjamin ThieleMarie KlosterMalik Alawi, Daniela Indenbirken, Martin TrepelAdam Grundhoff & Mascha Binder. (2014) Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma. Blood 123:23, pages 3618-3621.
Crossref
Roman Hajek, Samuel A. Okubote & Hana Svachova. (2013) Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. British Journal of Haematology 163:5, pages 551-564.
Crossref
Jonathan L. Kaufman, Ruben Niesvizky, Edward A. Stadtmauer, Asher Chanan-Khan, David Siegel, Heather Horne, William A. Wegener & David M. Goldenberg. (2013) Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British Journal of Haematology 163:4, pages 478-486.
Crossref
Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Sabina Russo, Bruna Greve, Vanessa Innao, Viviana Minardi & Caterina Musolino. (2013) Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. European Journal of Haematology 90:6, pages 441-468.
Crossref
Nathan G. Dolloff & Giampaolo Talamo. 2013. Impact of Genetic Targets on Cancer Therapy. Impact of Genetic Targets on Cancer Therapy 197 221 .
Yu-Tzu Tai. 2013. Advances in Biology and Therapy of Multiple Myeloma. Advances in Biology and Therapy of Multiple Myeloma 43 71 .
Hongyong Zhang, Juntao Luo, Yuanpei Li, Paul T. Henderson, Yanchun Wang, Sebastian Wachsmann-Hogiu, Weixin Zhao, Kit S. Lam & Chong-xian Pan. (2012) Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine: Nanotechnology, Biology and Medicine 8:7, pages 1116-1124.
Crossref
Jeffrey A. ZonderAnn F. MohrbacherSeema SinghalFrits van RheeWilliam I. Bensinger, Han Ding, John Fry, Daniel E. H. Afar & Anil K. Singhal. (2012) A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120:3, pages 552-559.
Crossref
Yu-Tzu Tai & Kenneth C. Anderson. (2011) Antibody-Based Therapies in Multiple Myeloma. Bone Marrow Research 2011, pages 1-14.
Crossref
Michel de Weers, Yu-Tzu Tai, Michael S. van der Veer, Joost M. Bakker, Tom Vink, Daniëlle C. H. Jacobs, Lukas A. Oomen, Matthias Peipp, Thomas Valerius, Jerry W. Slootstra, Tuna Mutis, Wim K. Bleeker, Kenneth C. Anderson, Henk M. Lokhorst, Jan G. J. van de Winkel & Paul W. H. I. Parren. (2011) Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology 186:3, pages 1840-1848.
Crossref
Robert B. Lorsbach. (2010) Update on the Diagnosis and Classification of the Plasma Cell Neoplasms. Surgical Pathology Clinics 3:4, pages 1061-1089.
Crossref
Grzegorz Wladyslaw Basak & Ewa Carrier. (2010) The Search for Multiple Myeloma Stem Cells: The Long and Winding Road. Biology of Blood and Marrow Transplantation 16:5, pages 587-594.
Crossref
Frits van Rhee, Susann M. Szmania, Myles Dillon, Anne M. van Abbema, Xin Li, Mary K. Stone, Tarun K. Garg, JuMei Shi, Amberly M. Moreno-Bost, Rui Yun, Balaji Balasa, Bishwa Ganguly, Debra Chao, Audie G. Rice, Fenghuang Zhan, John D. ShaughnessyJr.Jr., Bart Barlogie, Shmuel Yaccoby & Daniel E.H. Afar. (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics 8:9, pages 2616-2624.
Crossref
Jing Yang, Yabing Cao, Sungyongl Hong, Haiyan Li, Jianfei Qian, Larry W. Kwak & Qing Yi. (2009) Human-Like Mouse Models for Testing the Efficacy and Safety of Anti-β2-Microglobulin Monoclonal Antibodies to Treat Myeloma. Clinical Cancer Research 15:3, pages 951-959.
Crossref
J M Bergua, C Cabrera, E G Arteta & J Prieto. (2007) Reply to Gozzetti et al.. Leukemia 22:5, pages 1083-1084.
Crossref
J M Bergua, C Cabrera, E G Arteta & J Prieto. (2007) Rituximab in CD20 positive multiple myeloma. Leukemia 22:5, pages 1082-1083.
Crossref
Prashant Kapoor, Patricia T. Greipp, William G. Morice, S. Vincent Rajkumar, Thomas E. Witzig & Philip R. Greipp. (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. British Journal of Haematology 141:2, pages 135-148.
Crossref
Nikhil C. Munshi & Yu-Tzu Tai. 2009. Myeloma Therapy. Myeloma Therapy 167 202 .
Constantine S. Mitsiades, Patrick J. Hayden, Kenneth C. Anderson & Paul G. Richardson. (2007) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Practice & Research Clinical Haematology 20:4, pages 797-816.
Crossref
A Gozzetti, A Fabbri, S Lazzi, M Bocchia & F Lauria. (2007) Reply to Rituximab activity in CD20 positive multiple myeloma. Leukemia 21:8, pages 1842-1843.
Crossref
P Moreau, L Voillat, L Benboukher, C Mathiot, C Dumontet, N Robillard, O Hérault, F Garnache, R Garand, N Varoqueaux, H Avet-Loiseau, J L Harousseau & R Bataille. (2007) Rituximab in CD20 positive multiple myeloma. Leukemia 21:4, pages 835-836.
Crossref
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:1, pages 44-51.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.